Buying is seen across the healthcare space and the stock is likely to outperform in the coming sessions. “Looking at overall chart structure on the daily scale we expect the stock to move upwards towards 5050 zones from current levels with a stop loss below Rs 4600 zones on a closing basis in the next 3-4 weeks,” recommends Beriwal.
Lupin Q1 PAT rises 16 pc at Rs 1,417 cr
Lupin Ltd has reported a remarkable sixteen percent surge in profit after tax for the first quarter, showcasing their continued success. The firm experienced considerable